28.04.2015
amp biosimilars AG DE000A0SMU87
DGAP-News: amp biosimilars AG appoints Professor Dr. Dr. Rolf G. Werner as chairman of the Scientific Board
DGAP-News: amp biosimilars AG / Key word(s): Change of Personnel
amp biosimilars AG appoints Professor Dr. Dr. Rolf G. Werner as
chairman of the Scientific Board
28.04.2015 / 07:30
---------------------------------------------------------------------
amp biosimilars AG appoints Professor Dr. Dr. Rolf G. Werner as chairman of
the Scientific Board
- Former head of global biopharmaceuticals at Boehringer Ingelheim
- Honorary Senator and professor at the University of Tübingen
- Experience in the development of numerous biosimilars and
biopharmaceuticals
Hamburg, 28. April 2015 - amp biosimilars AG (ISIN: DE00A0SMU87), a company
specializing in the development of high quality biosimilars, has named
Professor Dr. Dr. Rolf G. Werner to head up the Scientific Board, effective
immediately. In his new role, Professor Werner will serve as the "Chairman
of the Scientific Board".
Rolf G. Werner is a Professor of Industrial Biotechnology and an Honorary
Senator at the Eberhard Karls University Tübingen. He is one of the world's
leading experts in research, development and production of pharmaceutical
biotechnologies, with more than 35 years of industry experience in various
leadership positions at Boehringer Ingelheim, including head of global
biopharmaceuticals. The company's more than 47,000 employees and revenues
of EUR 13.3 billion in 2014 make Boehringer Ingelheim the largest research
pharmaceutical company in Germany.
Prof. Werner's scientific contributions include more than 180 publications,
20 patents and 15 scientific films. His work has been honored with the City
of Vienna Prize for his outstanding contributions to science and by the
administrative district of Hangzhou, China, where he was named a Hangzhou
Qian Jiang Distinguished Expert.
"We are thrilled to have Professor Werner on our team," says Dr. Marc W.
Hentz, Chief Executive Officer of amp biosimilars AG. "His vast expertise
with every aspect of the development and production of biotechnological
materials and pharmaceuticals as well as his international network make him
the ideal partner to help identify and commercialize biosimilar
blockbusters."
"It is nothing less than a moral obligation to help find affordable,
efficient and safe high quality biosimilars that will give the general
global populace the means for improved quality of life, and I am happy to
be able to help in this regard," says Professor Werner, Honorary Senator at
the University of Tübingen.
The Scientific Board at amp biosimilars AG is currently composed of three
members and supports management with the implementation of its global
biosimilar development and commercialization strategy. In addition to its
chairman, Prof. Werner, the Scientific Board includes Dr. Holger Ziehr and
Dr. Xavier Luria. Dr. Ziehr, head of the Department of Pharmaceutical
Biotechnology at the ITEM Fraunhofer Institute, has previously developed
numerous biosimilars such as EPO, G-CSF and ß-interferon until the GMP
production. Dr. Luria has been the Head of Safety and Efficacy of Medicines
at the European Medicines Agency (EMA), where he coordinated international
Teams from the 28 EU member states in the regulatory evaluation of medical
products.
About amp biosimilars AG:
amp biosimilars AG develops high quality biosimilars to meet growing demand
on global therapeutic markets and is one of the most innovative and dynamic
biosimilar companies in Europe. The company is headquartered in Hamburg and
run by a team of leading industry experts. The development of a wide
variety of biosimilars will provide patients around the world with access
to life-improving and life-saving therapies. The combination of a research
platform with state-of-the-art analytics, process technology and clinical
expertise as well as regulatory know-how, makes amp biosimilars AG one of
the leading companies for biosimilar development and marketing. Thanks to
an international network of leading pharmaceutical companies, amp
biosimilars AG also has direct access to the strongest growing markets in
the world. With this approach amp biosimilars AG has a key position in one
of the fastest growing life science markets in the near future. amp
biosimilars AG has been listed on the Munich Stock Exchange since April 1,
2015. For more information please go to www.ampbiosimilars.com
Contact:
MC Services AG
Fabian Lorenz
T +49 211 529252-28
Email: [email protected]
---------------------------------------------------------------------
28.04.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
349293 28.04.2015
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
amp biosimilars AG ISIN: DE000A0SMU87 können Sie bei EQS abrufen
IT-Infrastruktur , A0SMU8 , NB2 , XETR:NB2